

**XTANDI is the first and only** androgen receptor inhibitor (ARI) approved by the FDA in 4 disease states in advanced prostate cancer—nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis, metastatic castration-sensitive prostate cancer, nonmetastatic castration-resistant prostate cancer, and metastatic castration-resistant prostate cancer.<sup>1</sup>



Not actual size of penny and tablets.

## XTANDI offers 2 once-daily dosing options to help meet your patients' needs<sup>1</sup>

The recommended dosage of XTANDI is 160 mg, taken orally, once daily as two 80 mg or four 40 mg tablets

### CONVENIENT DOSING AND STRAIGHTFORWARD ADMINISTRATION



#### Administration guidelines

- XTANDI can be taken at any time during the day but should be taken at the same time each day
- XTANDI can be taken with or without food
- Advise patients to take each capsule or tablet whole with a sufficient amount of water to ensure that all medication is successfully swallowed. Do NOT chew, dissolve, or open the capsules. Do NOT cut, crush, or chew the tablets
- If a dose of XTANDI is missed, inform patients that they should take it as soon as they remember
- If patients forget to take their dose for the whole day, then they should take their normal dose the next day
- Patients should not take more than their prescribed dose per day

#### Dose modifications to manage Grade 3-4 adverse reactions

- If a patient experiences a  $\geq$  Grade 3 or an intolerable adverse reaction, withhold XTANDI for 1 week or until symptoms improve to  $\leq$  Grade 2, then resume at the same or a reduced dose (120 mg or 80 mg) if warranted

#### Dose modifications for concomitant medications

- Avoid the coadministration of strong CYP2C8 inhibitors. If the coadministration of a strong CYP2C8 inhibitor cannot be avoided, reduce the XTANDI dosage to 80 mg once daily. If the coadministration of the strong inhibitor is discontinued, increase the XTANDI dosage to the dosage used prior to initiation of the strong CYP2C8 inhibitor
- Avoid the coadministration of strong CYP3A4 inducers. If the coadministration of a strong CYP3A4 inducer cannot be avoided, increase the XTANDI dosage from 160 mg to 240 mg orally once daily. If the coadministration of the strong CYP3A4 inducer is discontinued, decrease the XTANDI dosage to the dosage used prior to initiation of the strong CYP3A4 inducer

#### Indications

XTANDI is indicated for the treatment of patients with:

- nonmetastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR)
- metastatic castration-sensitive prostate cancer (mCSPC)
- castration-resistant prostate cancer (CRPC)

#### Select Safety Information

**Dysphagia or Choking** Severe dysphagia or choking, including events that could be life-threatening requiring medical intervention or fatal, can occur due to XTANDI product size. Advise patients to take each capsule or tablet whole with a sufficient amount of water to ensure that all medication is successfully swallowed. Consider use of a smaller tablet size of XTANDI in patients who have difficulty swallowing. Discontinue XTANDI for patients who cannot swallow capsules or tablets.

Please see [Important Safety Information](#) and [Full Prescribing Information](#).

#### Administer XTANDI orally, once daily

- ✓ **With no steroid requirement**
- ✓ **With no docetaxel requirement**
- ✓ **With or without food**
- ✓ **Without dose adjustments for patients with mild to severe hepatic or mild to moderate renal impairment**

- XTANDI has not been studied in patients with severe renal impairment (creatinine clearance  $<$  30 mL/min) or end-stage renal disease
- No clinically meaningful differences in the pharmacokinetics of XTANDI were observed based on hepatic impairment (Child-Pugh A, B, and C)

#### For treatment of patients with nmCSPC with high-risk BCR

- **Patients with nmCSPC with high-risk BCR may be treated with or without GnRH therapy\***
- Treatment can be suspended if PSA is undetectable ( $<$  0.2 ng/mL) after 36 weeks of therapy
- Reinitiate treatment when PSA has increased to  $\geq$  2.0 ng/mL for patients who had prior radical prostatectomy or  $\geq$  5.0 ng/mL for patients who had prior primary radiation therapy

**Patients with mCSPC or CRPC receiving XTANDI should also receive a gonadotropin-releasing hormone analog concurrently or should have had bilateral orchiectomy**

PSA, prostate-specific antigen.

\*Leuprolide.<sup>1</sup>

Learn more at [XtandiHCP.com](http://XtandiHCP.com)

The Warnings and Precautions for XTANDI include Seizure, Posterior Reversible Encephalopathy Syndrome (PRES), Hypersensitivity, Ischemic Heart Disease, Falls and Fractures, Embryo-Fetal Toxicity, and Severe Dysphagia or Choking Related to Product Size.<sup>1</sup> Additional information about these Warnings and Precautions can be found within this asset.

 **Xtandi**<sup>®</sup>  
(enzalutamide)  
40 mg tablets | 80 mg tablets

## Indications

XTANDI is indicated for the treatment of patients with:

- nonmetastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR)
- metastatic castration-sensitive prostate cancer (mCSPC)
- castration-resistant prostate cancer (CRPC)

## Important Safety Information

### Warnings and Precautions

**Seizure** occurred in 0.6% of patients receiving XTANDI in eight randomized clinical trials. In a study of patients with predisposing factors for seizure, 2.2% of XTANDI-treated patients experienced a seizure. It is unknown whether anti-epileptic medications will prevent seizures with XTANDI. Patients in the study had one or more of the following predisposing factors: use of medications that may lower the seizure threshold, history of traumatic brain or head injury, history of cerebrovascular accident or transient ischemic attack, and Alzheimer's disease, meningioma, or leptomeningeal disease from prostate cancer, unexplained loss of consciousness within the last 12 months, history of seizure, presence of a space occupying lesion of the brain, history of arteriovenous malformation, or history of brain infection. Advise patients of the risk of developing a seizure while taking XTANDI and of engaging in any activity where sudden loss of consciousness could cause serious harm to themselves or others. Permanently discontinue XTANDI in patients who develop a seizure during treatment.

**Posterior Reversible Encephalopathy Syndrome (PRES)** There have been reports of PRES in patients receiving XTANDI. PRES is a neurological disorder that can present with rapidly evolving symptoms including seizure, headache, lethargy, confusion, blindness, and other visual and neurological disturbances, with or without associated hypertension. A diagnosis of PRES requires confirmation by brain imaging, preferably MRI. Discontinue XTANDI in patients who develop PRES.

**Hypersensitivity** reactions, including edema of the face (0.5%), tongue (0.1%), or lip (0.1%) have been observed with XTANDI in eight randomized clinical trials. Pharyngeal edema has been reported in post-marketing cases. Advise patients who experience any symptoms of hypersensitivity to temporarily discontinue XTANDI and promptly seek medical care. Permanently discontinue XTANDI for serious hypersensitivity reactions.

**Ischemic Heart Disease** In the combined data of five randomized, placebo-controlled clinical studies, ischemic heart disease occurred more commonly in patients on the XTANDI arm compared to patients on the placebo arm (3.5% vs 2%). Grade 3-4 ischemic events occurred in 1.8% of patients on XTANDI versus 1.1% on placebo. Ischemic events led to death in 0.4% of patients on XTANDI compared to 0.1% on placebo. Monitor for signs and symptoms of ischemic heart disease. Optimize management of cardiovascular risk factors, such as hypertension, diabetes, or dyslipidemia. Discontinue XTANDI for Grade 3-4 ischemic heart disease.

**Falls and Fractures** occurred in patients receiving XTANDI. Evaluate patients for fracture and fall risk. Monitor and manage patients at risk for fractures according to established treatment guidelines and consider use of bone-targeted agents. In the combined data of five randomized, placebo-controlled clinical studies, falls occurred in 12% of patients treated with XTANDI compared to 6% of patients treated with placebo. Fractures occurred in 13% of patients treated with XTANDI and in 6% of patients treated with placebo.

**Embryo-Fetal Toxicity** The safety and efficacy of XTANDI have not been established in females. XTANDI can cause fetal harm and loss of pregnancy when administered to a pregnant female. Advise males with female partners of reproductive potential to use effective contraception during treatment with XTANDI and for 3 months after the last dose of XTANDI.

**Dysphagia or Choking** Severe dysphagia or choking, including events that could be life-threatening requiring medical intervention or fatal, can occur due to XTANDI product size. Advise patients to take each capsule or tablet whole with a sufficient amount of water to ensure that all medication is successfully swallowed. Consider use of a smaller tablet size of XTANDI in patients who have difficulty swallowing. Discontinue XTANDI for patients who cannot swallow capsules or tablets.

## Adverse Reactions (ARs)

In the data from the five randomized placebo-controlled trials, the most common ARs ( $\geq 10\%$ ) that occurred more frequently ( $\geq 2\%$  over placebo) in XTANDI-treated patients were musculoskeletal pain, fatigue, hot flush, constipation, decreased appetite, diarrhea, hypertension, hemorrhage, fall, fracture, and headache. In the bicalutamide-controlled study, the most common ARs ( $\geq 10\%$ ) reported in XTANDI-treated patients were asthenia/fatigue, back pain, musculoskeletal pain, hot flush, hypertension, nausea, constipation, diarrhea, upper respiratory tract, infection, and weight loss.

In AFFIRM, the placebo-controlled study of metastatic CRPC (mCRPC) patients who previously received docetaxel, Grade 3 and higher ARs were reported among 47% of XTANDI-treated patients. Discontinuations due to ARs were reported for 16% of XTANDI-treated patients. In PREVAIL, the placebo-controlled study of chemotherapy-naive mCRPC patients, Grade 3-4 ARs were reported in 44% of XTANDI patients and 37% of placebo patients. Discontinuations due to ARs were reported for 6% of XTANDI-treated patients. In TERRAIN, the bicalutamide-controlled study of chemotherapy-naive mCRPC patients, Grade 3-4 ARs were reported in 39% of XTANDI patients and 38% of bicalutamide patients. Discontinuations with an AR as the primary reason were reported for 8% of XTANDI patients and 6% of bicalutamide patients.

In PROSPER, the placebo-controlled study of nonmetastatic CRPC (nmCRPC) patients, Grade 3 or higher ARs were reported in 31% of XTANDI patients and 23% of placebo patients. Discontinuations with an AR as the primary reason were reported for 9% of XTANDI patients and 6% of placebo patients.

In ARCHES, the placebo-controlled study of metastatic CSPC (mCSPC) patients, Grade 3 or higher ARs were reported in 24% of XTANDI-treated patients. Permanent discontinuation due to ARs as the primary reason was reported in 5% of XTANDI patients and 4% of placebo patients.

In EMBARK, the placebo-controlled study of nonmetastatic CSPC (nmCSPC) with high-risk biochemical recurrence (BCR) patients, Grade 3 or higher adverse reactions during the total duration of treatment were reported in 46% of patients treated with XTANDI plus leuprolide, 50% of patients receiving XTANDI as a single agent, and 43% of patients receiving placebo plus leuprolide. Permanent treatment discontinuation due to adverse reactions during the total duration of treatment as the primary reason was reported in 21% of patients treated with XTANDI plus leuprolide, 18% of patients receiving XTANDI as a single agent, and 10% of patients receiving placebo plus leuprolide.

**Lab Abnormalities:** Lab abnormalities that occurred in  $\geq 5\%$  of patients, and more frequently ( $> 2\%$ ) in the XTANDI arm compared to placebo in the pooled, randomized, placebo-controlled studies are hemoglobin decrease, neutrophil count decreased, white blood cell decreased, hyperglycemia, hypermagnesemia, hyponatremia, hypophosphatemia, and hypercalcemia.

**Hypertension:** In the combined data from five randomized placebo-controlled clinical trials, hypertension was reported in 14.2% of XTANDI patients and 7.4% of placebo patients. Hypertension led to study discontinuation in  $< 1\%$  of patients in each arm.

### Drug Interactions

**Effect of Other Drugs on XTANDI** Avoid coadministration with strong CYP2C8 inhibitors. If coadministration cannot be avoided, reduce the dosage of XTANDI.

Avoid coadministration with strong CYP3A4 inducers. If coadministration cannot be avoided, increase the dosage of XTANDI.

**Effect of XTANDI on Other Drugs** Avoid coadministration with certain CYP3A4, CYP2C9, and CYP2C19 substrates for which minimal decrease in concentration may lead to therapeutic failure of the substrate. If coadministration cannot be avoided, increase the dosage of these substrates in accordance with their Prescribing Information. In cases where active metabolites are formed, there may be increased exposure to the active metabolites.

Please see [Full Prescribing Information](#).

**Reference:** 1. XTANDI. Package insert. Northbrook, IL: Astellas Pharma US, Inc; 2025.